LYMTACs:chimeric small molecules repurpose lysosomal membrane proteins for target protein relocalization and degradation Nature Communications - LYMTACs are heterobifunctional small molecules that take advantage of lysosomal membrane proteins to degrade membrane targets via relocalization and lysosomal degradation,...

Check out how the Amgen Induced Proximity team repurpose lysosomal membrane proteins for targeted protein relocalization and degradation using LYMTAC molecules. Now published in @NatureComms. Congrats to @dnalawansha0509.bsky.social and team! #mycompany www.nature.com/articles/s41...

gorycz porażki. / dla My Company Polska nr 08, 2025 / #satyra #startup #goryczporażki #rozwój #mycompany #komiksprasowy

Risk of developing psoriatic arthritis in patients with psoriasis initiating treatment with different classes of biologics To investigate the risk of psoriatic arthritis (PsA) in plaque psoriasis (PsO) patients receiving different classes of biologics.A retrospective obser…

One more recent paper presented at the symposium sponsored by #mycompany at #ARA2025ASM, this one is by McGonagle and colleagues: www.sciencedirect.com/science/arti...

Thank you for the presentation, A/Prof Chandran!

And now a clinical discussion with the panel.

Characterisation of myeloid cells in circulation and synovial fluid of patients with psoriatic arthritis Psoriatic arthritis (PsA) is an inflammatory arthritis associated with psoriasis. Adding to studies focused on the role of T cells and macrophages, we sought to investigate the systemic activation of ...

Continuing on at the #ARA2025ASM symposium sponsored by #mycompany: what cells are in the synovium of Psoriatic Arthritis patients? A/Prof Chandran highlighted data and is discussing his recent paper: pmc.ncbi.nlm.nih.gov/articles/PMC...

GWAS meta-analysis of psoriasis identifies new susceptibility alleles impacting disease mechanisms and therapeutic targets - Nature Communications Psoriasis is a partially heritable skin disorder, the genetic basis of which is not fully understood. Here, the authors use genome-wide association meta-analysis to discover psoriasis susceptibility l...

Currently hearing from A/Prof Vinod Chandran, sponsored by #mycompany #ARA2025ASM including a discussion of his recently published study: www.nature.com/articles/s41.... If you are at ARA, we invite you to join us in Hall C

A roadmap for engagement and inclusion of LGBTQIA+ people in clinical research - Nature Medicine Clinical research should recruit participants from LGBTQIA+ populations, and this requires specific actions and policies to create affirming and welcoming environments.

Our mission @J&J is to understand how our medicines work in all pts. I’m honored to have contributed to this ground breaking paper in @naturemedicine.bsky.social identifying a roadmap for inclusion of #LGBTQIA+ individuals. @fenwayhealth.bsky.social #MyCompany

www.nature.com/articles/s41...

Brief Report: Preventing Infusion-related Reactions With Intravenous Amivantamab: Results From SKIPPirr, a Phase 2 Study Amivantamab, an EGFR–MET bispecific antibody, is approved for multiple indications in EGFR-mutated advanced non-small cell lung cancer (NSCLC) as mono…

Excited to share our #SKIPPirr study was just published. Great job everyone involved in this study. #EGFR #NSCLC #PatientFocus #MyCompany
www.sciencedirect.com/science/arti...

JLABS x OBIO Funders and Founders Showcase | OBIO Annual Investment Summit For more info...

Attention Canadian life sciences + health innovators: #JLABS @ Toronto #Funders & #Founders Feb 5

Funders pitch their investment #strategies to #startups, #entrepreneurs
+
JLABS residents Poster Session

Link: jlabsfundersfoundersshowcase.splashthat.com

#mycompany #LifeSciences #Biotech #Medtech

I'm struggling to mess up my freshly cleaned studio. And it feels like a Friday for some reason. So, I'm taking a day off from writing. A day of music and maybe a break for frigid, but fresh, air feels like what I need instead. These books aren't going anywhere.
#writesky #selfemployed #mycompany

"Another positive result has been a feeling of increased psychological safety. Although we have never cultivated formality, having a management team at all imposes an implicit hierarchy of different levels of importance on employees. The structure of teams feels more equal."
#MyCompany

Great to speak at the @statnews.bsky.social panel Stat@ash on our goals in #hematology driving towards transforming outcomes in cancer. #MyCompany

Excited to be speaking on the @statnews.bsky.social panel this evening at #ASH24. Speaking on the innovations in hematology that Johnson & Johnson Innovative Medicine are leading and pioneering. #MyCompany

Great to see the Bleximenib data being presented here at #ASH24! More progress is needed in AML! #MyCompany

Come and join the J&J sponsored satellite symposium here at #IOHK24. Great speaker line up. #MyCompany

Heading to #ASH24? Love to connect and reconnect with anyone going. Johnson & Johnson Innovative Medicine team will be there in full force, presenting new data across our hematology portfolio. #Mycompany

Proud of this win for @amgen! #mycompany

GOOD NEWS ALERT! @Amgen is a finalist in the #SocialMedia category of the @PM360online 2022 Pharma Choice Awards for our outstanding work on the launch of Amgen TikTok. Winners are decided by vote. Please Vote!

#MyCompany

Filmed on campus today some TikToks. I’m really excited for this batch. #mycompany

Wrapping Up Amgen’s “Summer of Science” Instagram Series #mycompany

A Look Back at the Inspiring “People of Amgen” Series on Instagram #mycompany

Went on a lab tour today! 🥼 🧪 🧫 @Amgen is doing some awesome stuff and I’m so proud to be apart of it. #MyCompany

Proud to work at a company that flies the Pride flag! #mycompany @Amgen

Proud of @Amgen for taking a stand and signing this. #MyCompany #lovewinsoverhate

Business Statement on Anti-LGBTQ State Legislation via @HRC